Physician profile
James A Ware
NPI 1356449177
$9,346.85
in general payments reported to CMS, 2019-2025
69 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $1,101 · 2021: $1,927 · 2022: $1,252 · 2023: $1,353 · 2024: $973 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,080.08 | 2019-2025 | |
| Abbvie INC. | $868.03 | 2020-2025 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $864.51 | 2019-2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $663.46 | 2020-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $371.01 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $324.23 | 2021 | |
| Alexion Pharmaceuticals, INC. | $302.48 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $254.50 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $237.82 | 2019-2025 | |
| Allergan, INC. | $229.41 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $228.49 | 2019-2025 | Ongentys, Ingrezza |
| Sk Life Science, INC. | $209.13 | 2020-2025 | |
| Pfizer INC. | $189.36 | 2023-2025 | |
| Ucb, INC. | $183.30 | 2019-2025 | Rystiggo |
| Csl Behring | $171.42 | 2021-2025 | Hizentra |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.